hexamine micro methenamine hippurate 1 g tablet blister pack
micro labs pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; magnesium stearate - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.
hiprex- methenamine hippurate tablet
validus pharmaceuticals llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - hiprex is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of hiprex and other antibacterial drugs, hiprex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. hiprex (methenamine hippurate tablets usp) is contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to patients taking sulfonamides becau
hiprex- methenamine hippurate tablet
validus pharmaceuticals llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - hiprex is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of hiprex and other antibacterial drugs, hiprex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. hiprex (methenamine hippurate tablets usp) is contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to patients taking sulfonamides becau
hiprex methenamine hippurate 1g tablet
inova pharmaceuticals (australia) pty ltd - methenamine hippurate, quantity: 1 g - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; magnesium stearate - supression or elimination of bacteriuria associated with chronic or recurrent infection of the urinary tract, especially when long term therapy is indicated.
methenamine hippurate 1g tablets
alliance healthcare (distribution) ltd - methenamine hippurate - oral tablet - 1gram
methenamine hippurate 1g tablets
medihealth (northern) ltd - methenamine hippurate - oral tablet - 1gram
methenamine hippurate 1g tablets
brown & burk uk ltd - methenamine hippurate - oral tablet - 1gram
methenamine mandelate tablet
edenbridge pharmaceuticals llc. - methenamine mandelate (unii: 695n30cinr) (methenamine - unii:j50oix95qv) - methenamine mandelate 500 mg - methenamine mandelate, usp is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. when used as recommended, methenamine mandelate, usp is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. pathogens resistant to other antibacterial agents may respond to methenamine mandelate, usp because of the nonspecific effect of formaldehyde formed in an acid urine. prophylactic use rationale: urine is a good culture medium for many urinary pathogens. inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. there is a growing body of
hiprex
inova pharmaceuticals (new zealand) limited - methenamine hippurate 1 g (1.005g hexamine hippurate with aerosil); ; ; - tablet - 1 g - active: methenamine hippurate 1 g (1.005g hexamine hippurate with aerosil) excipient: magnesium stearate povidone - label claim: prophylaxis or supression of urinary tract bacteria
uramet methenamine hippurate 1 g tablet bottle
aspen pharmacare australia pty ltd - methenamine hippurate, quantity: 1 g - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica - suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract. may be used for short or long term therapy, as necessary.